Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy. HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gynecol Oncol Rep
Autors principals: Lee, Elizabeth K., Tan-Wasielewski, Zhenying, Matulonis, Ursula A., Birrer, Michael J., Wright, Alexi A., Horowitz, Neil, Konstantinopoulos, Panagiotis A., Curtis, Jennifer, Liu, Joyce F.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Case Series
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6712364/
https://ncbi.nlm.nih.gov/pubmed/31467965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2019.07.010
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars